Darolutamide slows spread of castration-resistant prostate cancer
(HealthDay)—Metastasis-free survival is significantly longer among men with nonmetastatic, castration-resistant prostate cancer treated with darolutamide versus placebo, according to a phase 3 study published online Feb. ...
Feb 19, 2019
0
1